Does autoimmunity against thyroglobulin play a role in the pathogenesis of Graves’ ophthalmopathy: a review

Thayalini Shanmuganathan1
Christian Girgis2
Hooshang Lahooti1
Bernard Champion1
Jack R Wall1
1Department of Medicine, Nepean Clinical School, Nepean Hospital, The University of Sydney, Sydney, 2Department of Medicine, Westmead Millennium Institute, The University of Sydney, Sydney, NSW, Australia

Abstract: While most authors believe that autoimmunity against the TSH receptor expressed in the orbital connective tissue cells is the main reaction that leads to the development of ophthalmopathy in patients with Graves’ hyperthyroidism, an older hypothesis that deserves fresh consideration is based on the notion that thyroglobulin (Tg) in the thyroid gland passes in a retrograde fashion to the orbit where it is recognized by Tg autoantibodies, leading to inflammation. Here, we review new evidence that supports a role of Tg and propose a new hypothesis based on the notion that Tg is targeted in the orbit leading to a complex cascade of reactions that leads to Graves’ ophthalmopathy.

Keywords: ophthalmopathy, Graves’ disease, thyroglobulin, thyroid peroxidase, TSH receptor, lymphocytes, autoantibodies

Introduction
The pathogenesis of the ophthalmopathy that occurs in approximately 40% of patients with Graves’ hyperthyroidism1 and, less often and usually in a less severe form, in 25% of patients with Hashimoto thyroiditis2 remains controversial.3,4 While most authors favor the hypothesis that autoimmunity against the TSH receptor (TSHr) expressed in the orbital fibroblasts, preadipocytes, and fibrocytes is the dominant autoimmune reaction that leads to orbital inflammation5–7 not all the evidence supports this, namely, Graves’ disease and worsening ophthalmopathy may be associated with decreasing levels of TSHr antibodies in individual patients (Wall et al, 2013, unpublished observations) and ophthalmopathy may develop many years after the onset of hyperthyroidism. Most importantly, patients with so-called euthyroid Graves’ disease8 have a similar ophthalmopathy but no evidence for thyroid autoimmunity including negative TSHr antibodies as measured in the TRAb assay and as thyroid-stimulating immunoglobulin in a Thyreporter bio-assay,9 suggesting that other possibilities should be considered. Moreover on a recent case report we showed that eye signs and other soft tissue manifestations of Graves’ disease worsened in the context of psychological stress, with reduced levels of TSHr antibody, occurred following stress.10

Regardless of the nature of the inflammatory process in the orbital connective tissue and fat and extra ocular muscles (EOM), the eye disorder is presumed to begin in the thyroid since the great majority of patients with Graves’ ophthalmopathy (GO) have active thyroid inflammation, ie, thyroiditis, at the time they develop eye signs.1,11 Thus, a logical hypothesis for the orbital reaction is that thyroid antigens are released in the context of a thyroiditis and travel (“home”) to the orbital tissues where they bind to various cell types and are targeted by autoantibodies and/or sensitized...
T cells, leading to orbital inflammation. This is the working hypothesis for most groups working on ophthalmopathy and has been well studied for the TSHr, but the possible role of the other major thyroid antigen, thyroglobulin (Tg), has been largely ignored.

**The Kriss hypothesis**

An earlier hypothesis for the development of ophthalmopathy in patients with Graves’ hyperthyroidism was developed by Konishi et al and McDougall and Kriss and based on the notion that Tg released from the thyroid gland might pass to the orbit via the putative lymphatics that link the thyroid to the orbit, where it could be recognized by Tg autoantibodies leading to orbital inflammation. Feldt-Rasmussen et al demonstrated the presence of Tg in the orbit but the presence of Tg/anti-Tg immune complexes has not been reported. Serum anti-Tg antibodies did not correlate closely with severity of the eye disease in one study.

Subsequently, using a panel of well-characterized monoclonal antibodies against Tg and patients sera, we demonstrated reactivity against a human orbital connective tissue membrane protein which correlated with serum anti-Tg antibody levels but not ophthalmopathy. We concluded that the orbital protein was not native Tg but another putative thyroid and orbital tissue shared antigen. In retrospect, these early studies had partly confirmed the hypothesis of McDougall and Kriss. Later, we carried out further studies with anti-Tg monoclonal antibodies to test for the presence of Tg in orbital tissues from patients with GO and, as controls, from patients undergoing orbital surgery for non-immunological disorders. However, we could not identify intact Tg in the orbit. Goh et al found that ophthalmopathy tended to be associated with lower titers of Tg and TPO antibodies in patients with Graves’ disease compared to those without eye involvement. Although they postulated that Tg antibodies somehow protected against ophthalmopathy, an alternative explanation is that serum antibodies are decreased in the circulation because they are absorbed out by Tg in the orbital tissues.

The “Tg hypothesis” lay dormant for a further 15 years until an Italian group reported a series of experiments in which they used monoclonal antibodies against Tg that identified intact Tg in the retro-orbital tissue from three patients with GO by Western Blotting and ELISA. They did not find Tg and anti-Tg immune complexes in the orbit and concluded that autoimmunity against Tg was probably a factor in the development of ophthalmopathy but likely cell mediated. A year later the same group carried out additional studies in more patients with GO, again identifying intact Tg in fibroadipose tissue from three of seven patients by immunoprecipitation and Western Blotting with Tg monoclonal antibodies. They did not detect Tg in EOM extracts, similar to our own earlier findings in which eye muscle membranes did not react with our Tg monoclonal antibodies. They also demonstrated intact Tg in sub-palpebral skin extracts from two of two patients with GO and they suggested that we should re-visit the Kriss hypothesis and the possibility that Tg is an important target for the autoimmune reactions in ophthalmopathy.

On the other hand, Kendall-Taylor et al identified an IgG which they called “ophthalmopathic immunoglobulin” that bound to retro-orbital but not to thyroid membranes, thyroid microsomes, or Tg. They concluded that GO was associated with what they called a “specific ophthalmopathic immunoglobulin” that reacted with retro-orbital antigen, as distinct from thyroid antigens, suggesting that the ophthalmopathy was an entity distinct from autoimmune thyroid disease.

**Serum Tg levels and ophthalmopathy**

Very recently, we demonstrated a significant positive correlation between serum Tg levels and the presence and severity of ophthalmopathy in patients with Graves’ disease. In patients with Graves’ disease, but not Hashimoto thyroiditis, Tg levels also correlated with serum titers of TSHr antibodies, favoring the notion that not only TSHr but also Tg, may be released from the thyroid gland in the course of a thyroiditis and home to the orbit where they become targets of autoantibodies and cytotoxic T lymphocytes.

**Special nature of the orbital fibroblasts**

Smith, Smith et al, Fernando et al, and Smith et al have convincingly demonstrated that orbital fibroblasts from patients with GO respond differently to skin fibroblasts and orbital fibroblasts from normal subjects in vitro. However, the fibroblasts may actually be the same in all situations but different in GO only because they have been primed in the context of the orbital reaction and have new surface markers which makes them seem different, ie, we need to differentiate between cause and effect before promoting the GO orbital fibroblasts, preadipocytes, and fibrocytes as “unique”. However, if considered in this light, the results described by Smith et al are compatible with, and supportive of, the “thyroid antigen hypothesis”.

While an effect of cytotoxic antibodies targeting Tg bound to EOM cells or orbital fibroblasts is one possible
mechanism for the initialization of orbital inflammation, there are other potential mechanisms for reactivity against Tg (and other thyroid antigens) in situ in the orbit. While it is known that orbital fibroblasts can be stimulated by TSHr antibodies in vitro, suggesting that the prominent orbital scarring and glycosaminoglycans overproduction of GO is due to a reaction with the TSHr, this could also result from a reaction between Tg antibodies and Tg attached to the orbital fibroblasts; more likely, both mechanisms contribute to the orbital pathology and clinical features (Table 1).

Thyroiditis and ophthalmopathy

Subacute thyroiditis and radioiodine treatment of Graves’ hyperthyroidism may be good models for what may happen to the orbit in patients with thyroiditis. What happens to the thyroid gland following radioactive iodine treatment of patients with Graves’ hyperthyroidism. Following 131I, there is a flare up in the thyroiditis with release of thyroid proteins and increased production of the corresponding antibodies, against Tg, TPO, and the TSHr. In addition, we have recently shown an increase in serum Tg concentrations following radioiodine which correlated with an increase in TSHr antibody titer, initial worsening of the eye signs, but later improvement (Wall et al, 2013, unpublished observations). It is also likely, but not yet shown, that the numbers of thyroid antigen-sensitized T cells increase in the thyroid following 131I treatment; antibodies and sensitized T cells could pass to the orbital tissues, leading to a flare up in the severity of existing eye disease. Indeed, studies confirming that radioactive iodine treatment leads to worsening of eye signs – or even the new development of ophthalmopathy, although this is more controversial – would be good evidence for a role of autoimmunity against thyroid antigens in the development of ophthalmopathy in patients with thyroid autoimmunity.

While there is no mechanistic data that radioactive iodine worsens GO by increasing thyroid destruction, release of Tg, and production of Tg/anti-Tg immune complex, this is our working hypothesis for present in vitro and clinical studies (Table 2). In the longer term, one would expect a decrease in the severity of the ophthalmopathy as the “thyroid antigen mass” is destroyed by 131I, and this has been shown in earlier observations that total thyroidectomy is associated with the improvement of existing eye disease and prevention of new ophthalmopathy.

While this review focuses on the role of Tg, we believe that there are other thyroid antigens that are involved in the pathogenic process of GO. This process can be characterized as a complex series of reactions involving multiple thyroid antigens, the corresponding serum autoantibodies, cellular immunity, cytokines, and a large number of other chemical mediators and co-factors. Our proposed hypothesis for the role of Tg in the development of ophthalmopathy in patients with thyroid autoimmunity is shown schematically in Figure 1.

Figure 1 Hypothetical role of thyroglobulin in Graves’ ophthalmopathy.
Table 1 Evidence supporting a role of thyroglobulin in the pathogenesis of Graves’ ophthalmopathy

| Evidence                                                                 | Graves’ Ophthalmopathy |
|-------------------------------------------------------------------------|------------------------|
| 1. Thyroglobulin is a large and very antigenic protein and the corresponding autoantibodies react with it in many clinical and experimental situations, so why not in the orbit? | Graves’ ophthalmopathy so would be seen by circulating thyroglobulin antibodies |
| 2. Intact thyroglobulin can be detected in the orbits of patients with Graves’ ophthalmopathy | Graves’ ophthalmopathy so would be seen by circulating thyroglobulin antibodies |
| 3. In patients with Graves’ hyperthyroidism, serum thyroglobulin levels correlate with the prevalence and severity of any associated ophthalmopathy | Graves’ ophthalmopathy so would be seen by circulating thyroglobulin antibodies |
| 4. In patients with Graves’ ophthalmopathy, serum thyroglobulin levels correlate with serum titers of TSHr antibodies | Graves’ ophthalmopathy so would be seen by circulating thyroglobulin antibodies |
| 5. In patients with Graves’ ophthalmopathy, serum thyroglobulin levels correlate with TSHr antibody titers, suggesting that both thyroid antigens are released at the same time | Graves’ ophthalmopathy so would be seen by circulating thyroglobulin antibodies |
| 6. Thyroglobulin antibodies in the circulation and from the thyroid would bind to Tg in the orbit, although this has not been demonstrated | Graves’ ophthalmopathy so would be seen by circulating thyroglobulin antibodies |

Abbreviation: TSHr, TSH receptor.

Role of chemokines in GO

The importance of chemokines such as CXCL10 and CCL2 on GO has been investigated by the Italian team. They have demonstrated that EOM involves in the self-perpetuation of inflammation by secreting CXCL10 and CCL2 chemokines under the influence of cytokines especially IFNγ. In addition to that, CXCL9 and CXCL10 have been assessed as surrogate markers of GO while patients undergoing treatment and were proposed to be useful guidelines in therapeutic decision-making.

Future studies

The evidence for a role of autoimmunity against Tg is, as is the case for the TSHr, mainly circumstantial. In order to prove the “thyroid antigen hypothesis”, we must demonstrate that normal orbital fibroblasts and EOM cells, to which are attached Tg, become targets for antibodies and/or sensitized T lymphocytes from patients with ophthalmopathy, but not from those without eye disease. We can compare GO patient sera vs normal sera, fibroblasts to which is bound Tg vs control antigen and peripheral blood mononuclear cells, or purified T-cell subsets from patients with GO vs those from patients with Graves’ disease without eye signs. We can also isolate mononuclear cells from the thyroid of patients with GO and test for reactivity against the same target cells vs mononuclear cells from patients with Graves’ disease without ophthalmopathy. Specific IgG autoantibodies obtained by affinity chromatography, and purified subpopulations of T cells targeting Tg can be incubated with Tg-coated EOM cells or orbital fibroblasts to confirm findings using serum and unfractionated mononuclear cells. As end points, one can measure changes in gene expression for inflammatory markers and cytokine levels. It is also possible to study the putative benefits of selenium supplementation in GO in this model. We can carry out serial studies of patients with Graves’ hyperthyroidism, measuring serum Tg antibodies and correlating with eye signs. The notion that Tg antibodies tend to be low in patients with ophthalmopathy and those without eye disease due to their absorption by the orbital tissues can be studied by correlating orbital Tg levels in immunohistochemistry with parameters of the orbital autoimmune reactions, scores for eye signs, and serum Tg and anti-Tg titers in serial studies of patients with and without ophthalmopathy, including those treated with radioactive iodine.

Conclusion

The orbital reactions in patients with Graves’ disease are complex, involving antibodies and T lymphocytes, as well as other mononuclear cells, homing receptors on orbital cells, and cytokines. Moreover, we must determine why it is that only approximately 50% of patients with Graves’ hyperthyroidism develop ophthalmopathy. Environmental and genetic factors will play a role, an example being the presence of a recently shown informative single nucleotide polymorphism in the CASQ1 gene which is linked to ophthalmopathy. Smoking is well recognized as a major risk factor for ophthalmopathy and stress is likely to play an important role in its initiation. In conclusion, it does seem appropriate to give serious attention to the possibility that the pathogenesis of GO is not just about the TSHr but the contribution from Tg and other thyroid antigens as well.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid. 2002;12:855–860.
2. Tjiang H, Lahooti H, McCrorquodale T, Parmar KR, Wall JR. Eye and eyelid abnormalities are common in patients with Hashimoto’s thyroiditis. Thyroid. 2010;20:287–290.
3. Wall J. Thyroid function: news and views: pathogenesis of Graves’ ophthalmopathy – a role for TSH-R? Nat Rev Endocrinol. 2014;37:256–258.

4. Girgis CM, Champion BL, Wall JR, Girgis C, Champion B, Wall J. Current concepts of Graves’ disease: a review. Ther Adv Endocrinol Metab. 2012;2:135–144.

5. Weetman AP. Graves’ disease. N Engl J Med. 2000;342:1236–1248.

6. Eckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006;91:3464–3470.

7. Paschke R, Vassart G, Ludgate M. Current evidence for and against the TSH receptor being the common antigen in Graves’ disease and thyroid associated ophthalmopathy. Clin Endocrinol (Oxf). 1995;42:565–569.

8. McCrorquodale T, Lahooti H, Gopinath B, Wall JR. Long term follow-up of seven patients with ophthalmopathy not associated with thyroid autoimmunity – heterogeneity of autoimmune ophthalmopathy. Clin Ophthamol. 2012;6:1–9.

9. Lahooti H, Houtz JA, Tran YC, et al. TSH receptor antibodies as measured in a thyroid stimulating immunoglobulin (TSI) reporter bioassay are not detected in patients with euthyroid Graves’ disease. Austin J Ophthamol. 2014;14:1–7.

10. Girgis CM, Champion BL, Wall JR. Psychological stress and soft-tissue manifestations of Graves disease: a potential link? AACE Clin Case Rep. In press 2015.

11. Bartley GB, Fatourechi V, Kadmars EF, et al. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthamol. 1996;121:284–290.

12. Konishi J, Herman MN, Kriss JP. Binding of thyroglobulin and thyroglobulin-anti thyroglobulin complex to extracellular muscle membrane. Endocrinology. 1974;95:434–446.

13. McDougall IR, Kriss JP. New thoughts about the cause and treatment of the severe ocular manifestations of Graves’ disease. Scot Med J. 1974;19:165–169.

14. Feldt-Rasmussen U, Kemp A, Bech K, Madsen AN, Date J. Serum thyroglobulin, its autoantibody and thyroid stimulating antibodies in the endemic exophthalmos Acta Endocrinol (Copenh). 1981;96:192–198.

15. Kuroki T, Ruif T, Whelan L, Miller A, Wall JR. Antibody response to thyroglobulin monoclonal and autoantibodies cross-reactivity on orbital connective tissue antigen. A possible mechanism for the association of ophthalmopathy with autoimmune thyroid disorders. Clin Exp Immunol. 1985;69:931–936.

16. Kodama K, Sikorska H, Baily R, Bandy-Dafoe P, Wall J. Use of monoclonal antibodies to investigate a possible role of thyroglobulin in the pathogenesis of Graves’ ophthalmopathy. J Clin Endocrinol Metab. 1974;59:67–73.

17. Goh SY, Ho SC, Seah LL, Fong KS, Kho KH. Thyroid autoantibody profiles in ophthalmic dominant and thyroid dominant Graves’ disease differ and suggest ophthalmopathy is a multi antigenic disease. Clin Endocrinol (Oxf). 2004;60:600–607.

18. Marino M, Lisi S, Pinchera A, et al. Identification of thyroglobulin in orbital tissues of patients with thyroid-associated ophthalmopathy. Thyroid. 2001;11:177–185.

19. Marinò M, Chiovato L, Lisi S, et al. Role of thyroglobulin in the pathogenesis of Graves’ ophthalmopathy: the hypothesis of Kriss revisited. J Endocrinol Invest. 2004;27:230–236.

20. Kendall-Taylor P, Atkinson S, Holcombe M. Specific IgG in Graves’ ophthalmopathy and its relation to retro-orbital and thyroid autoimmunity. BMJ. 1984;288:1183–1186.

21. Lahooti H, Shanmuganathan T, Champion B, Wall JR. Serum thyroglobulin levels in patients with thyroid autoimmunity with and without ophthalmopathy or isolated upper eyelid retraction. Int Trends Immun. 2015;3:22–27.

22. Smith TJ. TSH-receptor-expressing fibrocytes and thyroid associated ophthalmopathy. Nat Rev Endocrinol. 2015;11:171–181.
